The broker raised its price target for the software company to $1,875 from $990 and maintained its buy rating on the stock.Markets, news, MicroStrategy, Analyst Ratings, stock pricesRead More

You might also be interested in reading Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding.